Predicting ILD from Hypersensitivity Pneumonitis

Trial Objective

Predicting ILD from Hypersensitivity PneumonitisResearchers believe they will be able to predict which patients with chronic Hypersensitivity Pneumonitis (HP) will develop interstitial lung disease (ILD) by looking at their genes and biomarkers in their blood. For this observational study, researchers will collect samples and data from participants with rapidly progressing HP and slowly progressing HP to look for patterns that can help predict the development of ILD and form specialized treatment plans.


New enrollment for this trial is temporarily paused

Who Can Participate

Adults who have been diagnosed with Hypersensitivity Pneumonitis (HP).

Age: 18-90    Gender: Any Gender

Estimated Time Commitment

Clinic visits every 6 months over approximately 2 years (4 visits total)

Payment & Reimbursement  

Payment: Not Provided

Travel Reimbursement: Not Available

Trial Contact

For more information, contact:

Melissa Schwab

Melissa Schwab

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Investigator Initiated with funding from Boehringer Ingelheim

Principal Investigators


Request More Information

After limiting clinical research activity due to safety concerns about COVID-19, we are now restarting clinical research in stages. If you are interested in any of the clinical trials posted on our website, please request trial information. We will respond and share the timing for enrollment resuming. Learn More